Sunshine Biopharma, Inc.
SBFM
$1.05
$0.021.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -142.24% | 50.09% | -50.09% | 45.33% | -80.18% |
| Total Depreciation and Amortization | 2.49% | 32.69% | 11.88% | -0.92% | 1.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -74.40% | -47.76% | -- | -- | -- |
| Change in Net Operating Assets | 157.46% | 22.31% | -6.34% | 54.37% | -487.47% |
| Cash from Operations | -122.04% | 42.85% | 25.70% | 49.67% | -151.02% |
| Capital Expenditure | 112.50% | 95.00% | -2,033.33% | 92.69% | 80.15% |
| Sale of Property, Plant, and Equipment | -200.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 65.98% | 63.68% | -96.91% | -3,610.42% | 103.13% |
| Cash from Investing | 57.57% | 75.95% | -179.43% | -79.96% | 85.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 229.28% | -239.53% | -- | -- |
| Issuance of Common Stock | -- | -100.00% | 932.54% | -78.04% | -14.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 859.60% | -97.91% | 967.79% | -79.11% | -17.18% |
| Foreign Exchange rate Adjustments | 432.28% | -168.01% | 3,391.18% | 98.39% | -182.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.67% | -145.81% | 239.62% | 38.02% | -460.58% |